You just read:

New DARZALEX® (daratumumab) Data from GRIFFIN Study Show High Response Rate and Depth of Response in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant-Eligible

News provided by

Janssen Pharmaceutical Companies of Johnson & Johnson

Sep 15, 2019, 08:00 ET